

Durham Research Online

Deposited in DRO:

06 May 2020

Version of attached file:

Accepted Version

Peer-review status of attached file:

Peer-reviewed

Citation for published item:

Ruggeri, Michele and Dombrowski, Amanda W and Djuric, Stevan W and Baxendale, Ian R. (2020) 'A rearrangement of 3-hydroxyazetidines into 2-oxazolines.', *Journal of organic chemistry.*, 85 (11). pp. 7276-7286.

Further information on publisher's website:

<https://doi.org/10.1021/acs.joc.0c00656>

Publisher's copyright statement:

This document is the Accepted Manuscript version of a Published Work that appeared in final form in *Journal of organic chemistry*, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see <https://doi.org/10.1021/acs.joc.0c00656>

Use policy

The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-profit purposes provided that:

- a full bibliographic reference is made to the original source
- a [link](#) is made to the metadata record in DRO
- the full-text is not changed in any way

The full-text must not be sold in any format or medium without the formal permission of the copyright holders.

Please consult the [full DRO policy](#) for further details.

Article

A rearrangement of 3-hydroxyazetidines into 2-oxazolines.

Michele Ruggeri, Amanda W Dombrowski, Stevan W Djuric, and Ian R. Baxendale

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.0c00656 • Publication Date (Web): 05 May 2020

Downloaded from pubs.acs.org on May 6, 2020

Just Accepted


"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.

A rearrangement of 3-hydroxyazetidines into 2-oxazolines.

Michele Ruggeri,^[a] Amanda W. Dombrowski,^[b] Stevan W. Djuric^[c] and Ian R. Baxendale*^[a].

[a] Prof. Ian R. Baxendale, Mr M. Ruggeri, Department of Chemistry, University of Durham, South Road, Durham, Durham, UK. DH1 3LE. E-mail: i.r.baxendale@durham.ac.uk [b] Dr A. W. Dombrowski, Discovery Chemistry and Technology AbbVie Inc. Waukegan Road, North Chicago, Illinois 60064. USA. [c] Dr S. W. Djuric, Discovery Chemistry and Technology Consulting LLC, New Bern, NC 28562.

KEYWORDS *heterocycles, Ritter Reaction, Cascade, Oxazoline.*




ABSTRACT: A novel rearrangement sequence of 3-hydroxyazetidines via a Ritter initiated cascade provides highly substituted 2-oxazolines in high yields. The reaction conditions and substrate scope of the transformation have been studied demonstrating the generality of the process. The derived products can also be functionalized in order to undergo further intramolecular cyclisation leading to a new class of macrocycle. The final cyclisation step was shown to be a transformation amenable to continuous flow processing allowing for a dramatic reduction in the reaction time and simple scale-up.

INTRODUCTION

In a recent report, we described the preparation of a range of 3-hydroxyazetidines accessed via an efficient photochemical Yang reaction processed under flow conditions (Scheme 1, 1→2).¹ Having successfully demonstrated the scope, versatility and scalability of the reaction, we were particularly interested in expanding the medicinal chemistry value of the compound collection by applying simple secondary transformations to conduct functional group interconversions. As the starting materials **2** all possess a prominent tertiary benzylic alcohol, we contrived to replace this group with an amide through a Ritter reaction.

Scheme 1. Formation of the 3-hydroxyazetidine via the Yang reaction and proposed Ritter reaction.



In a simple procedure, the substrate was refluxed in DCM (30 min) in the presence of 1 equivalent of sulfuric acid and an excess of acetonitrile. Although the reaction proceeded smoothly with full consumption of the starting material, to our initial surprise, the compound formed was a new cyclic, rearranged structure (90% isolated yield) which we determined to be a 2-oxazoline derivative (Scheme 1, Figure 1).





Figure 1. Compound **4-1** isolated from the attempted Ritter reaction of **2** (R = Me, for X-ray structure see SI).

To account for its formation, we propose a direct cascade sequence which initiates through a standard Ritter reaction. The intermediate Ritter amide (hydrolysis re-incorporates the displaced water from the 3-hydroxyazetidine) then rapidly undergoes further rearrangement; in which the amide carbonyl attacks and ring opens the azetidine, driven by the relaxation of the ring strain (Scheme 2).

Scheme 2. Proposed mechanism for the rearrangement of 3-hydroxyazetidines under Ritter type conditions.



Although this was not our intended transformation, this reaction represents a previously unreported and interesting rearrangement sequence leading in high yield to a set of novel oxazoline scaffolds. Oxazolines are an important class of heterocycle being prominent functional units in several biologically active molecules (antimicrobial,² anti-inflammatory,³ anti-malarial,⁴ antibacterial,⁵ antitumor,⁶ anti-viral,⁷ antipyretic,⁸ antituberculous,⁹ CNS stimulant activity,¹⁰ antioxidant¹¹) and several natural products.¹² In addition, they have found other uses as protective coatings (corrosion inhibitors), as additives in gasoline and lube oil, and as antifoaming agents.¹³ However, one of the most common uses of oxazolines is in asymmetric catalysis, where chiral oxazolines are widely used as ligands.¹⁴ Based upon our interest in the product structure and the simplicity of the reaction sequence, we elected to investigate the generality of the transformation which we report in full here.

RESULTS AND DISCUSSION

Optimization: Acid Screening

In an attempt to further optimize the reaction, we evaluated a range of acid sources to determine the impact on the transformation. Reactions were run with 1 equivalent of H₂SO₄, HBF₄, CH₃SO₃H and *p*-TSA giving respectively 90%, 85%, 40% and 35% isolated yield (standard 30 min reaction time). It should also be noted that substoichiometric quantities of acid gave comparable results but required the use of much extended reaction times; this was ultimately found to also be detrimental to the quality of the crude product which showed more decomposition over prolonged reaction times, equating to lower isolated yields. Other acids tested, such as acetic acid, CF₃CO₂H, polyphosphoric acid, Eaton's reagent (phosphorus pentoxide - methanesulfonic acid 10:1 wt) and camphorsulfonic acid were all completely ineffective, with no product being detected (>4 h reaction time), and the starting material being fully recovered (Note: we never observed the corresponding Ritter intermediate in any of these experiments). Attempting to employ a solution of HCl·Et₂O resulted in the slow formation of the corresponding chloro-substituted product **5** (Figure 2). In independent experiments, this was shown to exist in equilibrium with the parent alcohol. Thus, increasing the proportion of HCl over water in the mixture resulted in higher quantities of the resultant chloro product **5** being detected but never full conversion.




Figure 2. Reaction product obtained through treatment with hydrochloric acid (see SI for X-ray structure).

Catalysis of the transformation was also attempted employing several Lewis acids (1 equiv.), among these

FeCl₃, ZnCl₂, AlCl₃ and Cu(OTf)₂ all failed to promote any reaction, whereas BF₃·OEt₂ initially looked promising giving fast early reaction turnover but only giving ~50% conversion (38% isolated) as the reaction quickly stalled. We suspect that the boron trifluoride becomes rapidly deactivated by acting as a dehydrating agent preventing the desired reaction. Adding additional amounts of BF₃·OEt₂ (> 2 equiv.) continues to progress the reaction, although the reaction mixture become increasingly complex with decomposition products.

While the results obtained with H₂SO₄, CH₃SO₃H and *p*-TSA can be accounted for by their relative *p*K_a and dehydrating effect, the surprising outcome was with HBF₄ (48 wt% aqueous solution) which gave 85% based upon full consumption of the starting material. By contrast, dilution of the other acids i.e. H₂SO₄ with water led to a significant drop in reactivity and incomplete (stalled) reaction. This seems to confirm the interesting property of the HBF₄ aqueous solution as previously noted by Stutz *et al.*¹⁵ who found mixtures of HBF₄ (aq.) in acetonitrile was able to rapidly cleave acetals, BOC groups and *tert*-butyldimethylsilyl ethers within minutes at room temperature, and was more effective than many other acids/solutions of acids.

In summary, H₂SO₄ gave the best conversion and yield, thus, considering factors like safety, price and availability, it remains the best choice of catalyst for the transformation.




Figure 3. Investigation of substrate scope (Isolated yields).

Optimization: Solvent choice

Our solvent selection for the process was rather restricted due to reactivity and the solubility of the substrate and product. Chloroform was found to work equally well as DCM; ethyl acetate and THF could also be used, but the yields were reduced (~5-15%) and accompanied by unidentified minor impurities. Other potential solvents, such as toluene, xylenes, chlorobenzene and trifluorobenzene, were insufficiently solubilizing. Interestingly, the effect of reflux temperature between DCM and chloroform seemed to offer little advantage with both reactions being complete in ~10-12 minutes and yielding essentially identical product outcomes.


Substrate scope

Having determined the general reaction conditions, we next embarked upon an evaluation of the reaction scope in terms of both the azetidine and nitrile components. We were pleased to find the reaction proved general allowing a range of products to be assembled in good to high yield (Figure 3). The rapid rate of reaction (~10 min) and relatively mild conditions enabled several different

functional groups to be tolerated. In each case, the progression of the reaction was easily followed by LC-MS.

In general, simple alkyl and aryl nitriles worked well (**4-1** – **4-6**). Even basic and acidic containing functionalities proved amenable, although isolation involving neutralisation of the product mixture was more difficult and thus, resulted in lower recoveries (**4-10** – **4-12**, **4-15** – **4-18**). We also experienced issues with the isolation of compound **4-12**, which was produced as a mixed salt; additional optimisation beyond the proof of concept on this substrate was not performed. Finally, compound **4-18** could be isolated but required the use of excess acid as the hydration of the alkene competes with the protonation of the azetidine alcohol required for the carbocation formation (Scheme 3). As such, when only 1 equivalent of acid was used, a complex mixture of the alkene **6**, alcohol starting material **2** and the corresponding mixed hydrated products (**4-18**, **4-19**) was obtained. Whereas with an excess of acid (2.3 equiv.) selective conversion of the starting material to compound **4-18** in a respectable 81% isolated yield was achieved.

Scheme 3. Cascade sequence forming hydrated compound **4-18** (Product conversions were determined using an internal standard on the crude reaction mixtures).



Considering the positive results obtained, we considered the possibility of preparing dyad molecules through double addition to *bis*-nitrile precursors. These compounds were of general interest as potential ligands; as indicated in the introduction oxazoline are excellent metal binders and chelating systems possessing chirality would be of additional significance. Starting with 1,3-dicyanobenzene and using 2 equivalents of the azetidine (**2**, R= Me), we were initially surprised that no product from the double addition was detected. Instead, only a low yield (35%) of the mono oxazolidine **4-8** was produced. However, when observing a repeat reaction more closely, we attributed this to the poor solubility of the starting nitrile and its resulting single addition adduct **4-8**, which seemed to immediately precipitate upon formation. Overall, the limited dissolution resulted in poor mixing and ineffective reaction. Unfortunately, the use of DMF added to help solubilize the starting materials completely shut down the reaction, presumably by attenuating the pH. Other solvents or additives also failed to improve the situation.

We therefore selected a more soluble *bis*-nitrile starting material, glutaronitrile, which was subjected to the same reaction conditions. In this case, we successfully isolated from the reaction, 3 compounds; the meso **4-20** and racemic **4-21** diastereoisomers, confirmed by X-ray analysis along with the corresponding mono substituted oxazolidine **4-22** (Figure 4). These were formed in a ratio of 1:1:1.1, respectively, as determined by ^1H NMR analysis of the crude reaction mixture.




Figure 4 Reaction products of 1,3-dicyanopropane (glutaronitrile) with 3-hydroxazetidine **2** ($R = \text{Me}$) forming dyad molecules. X-ray images of **4-20** (left) and **4-21** (right) (Atomic displacement ellipsoids are drawn at the 50% probability level, for further X-ray data see SI).

The two dyads possess very different and interesting solid state and solution interactions, which due to their interesting structures and potential uses in supramolecular and materials chemistry we decided to explore them further. As can be seen from the single crystal X-ray representations (Figure 4), the racemic structure **4-21**, forms a set of complementary hydrogen bonds creating a tight dimeric pairing (oxazole to sulfonamide NH linkage). This interaction seems to also be observed in solution as evidenced by the ^1H NMR, where the NH signals appear at a high chemical shift of 9.17 ppm (2H, CDCl_3). This same synergistic interaction is absent in the meso compound **4-20**, instead only a single intramolecular hydrogen bond occurs, a bridging H-bonding methanol molecule helps form a secondary interaction in the solid-state structure (Figure 5, For full X-ray data see SI).




Figure 5. X-ray image of meso compound **4-20** showing the additional solvent (MeOH) H-bonding interaction, atomic displacement ellipsoids are drawn at the 50% probability level.


The corresponding ^1H NMR solution state NH signals of **4-20** gives rise to a much lower resonance at 7.06 ppm (2H, CDCl_3). This data is consistent with compound **4-20**

adopting a weaker set of hydrogen bond interactions. Indeed, this trend is completed when it is compared to the monomer **4-22** which shows a NH signal at 5.21 ppm (indicative of no H-bonding), this is also fully consistent with the other mono-oxazole structures (Figure 3), NH signal range 5-6.5 ppm). We therefore hypothesize that structure **4-20** is unable to hydrogen bond as tightly as **4-21** due to its mismatching stereochemistry (easily seen by comparing the X-ray forms, Figure 4) and as such adopts in solution a more dynamic structure allowing rapid exchange between the two sets of H-bonding sulfonamide and oxazole (equating to an average NH signal). This exchange process is potentially assisted by the presence of small H-bonding solvent molecules. This is exemplified when using extensively dried NMR solvent (CDCl_3). The recorded spectra of **4-20** gives broad and poorly resolved signals, yet with the addition of a H-donor/acceptor molecule i.e. H_2O or MeOH the signals immediately sharpen giving well defined patterns and coupling. We take this as an indication of a faster exchange process in the presence of the H-bonding capable molecule. In comparison, no effect is seen in the ^1H NMR for structures **4-21** or **4-22**.

Investigating Alternative Nucleophiles

Having established that the azetidine ring can be readily opened in an intramolecular process, we considered the possibility of creating other related cascades involving for example, an aromatic ring acting as the nucleophile (Scheme 4, compound **7** – **10**). We note that after this work had been performed, we became aware of an intramolecular by-product reported by Denis *et al.* which gives precedent to this type of ring opening in a similar context.¹⁶

Scheme 4. Products **7** – **10** obtained from using the use of aromatic nucleophiles.




Initial success was immediately achieved using 3- and 4-methoxyphenol, which each gave the rearrangement product as determined by NMR and later confirmed by single crystal X-ray analysis for compound **7**. However, when the alternative 3- and 4-methoxythiophenol was used, the azetidine was converted to the intermediate substitution product, but the secondary cyclisation was not observed, even after prolonged reaction times. We eventually managed to obtain an X-ray crystal structure of compound **9** (see SI for X-ray data) which clearly shows the long C-S bonds (C2/S2 1.825 & S2/C18 1.779 Å), this makes it impossible to adopt the correct alignment with sufficient orbital overlap between C23 – C1/C3 for the ring opening to occur. Considering the different aspects of the reaction we also speculatively attempted the reaction with the equivalent 3-/4-methoxy anilines but unfortunately no reaction was observed using either 0.5, 1 or 2 equivalents of acid catalyst.

Further Intramolecular Reactions

In our initial substrate scope experiments, we had shown it was feasible to carry a bromide appendage on the nitrile component, compound **4-9**. In addition, we explored the tosylamide nucleophilicity, which we expected to be good due to the high degree of sp^3 character suggested both by looking at the x-ray structure (Figure 1) and at the 1H -NMR NH shift and J values (NH coupling with the vicinal CH_2). To experimentally confirm the nucleophilic reactivity, we performed a displacement reaction on 2-bromo-1-(4-bromophenyl) ethanone (Scheme 5).

Scheme 5. Identification of *N*-nucleophilicity in the formation of compound **11**. The reaction yield was not optimised.



These observations and preliminary results led us to explore the use of nitrile precursors which would result in products containing residual alkyl halide chains generated from the Ritter cascade (Figure 6). Our proposal was that these could then enable an intramolecular substitution reaction furnishing very interesting bicyclic products.




Figure 6. Products of the azetidine rearrangement prepared with pendant alkyl bromide side chains.

We successfully prepared a series of suitable starting materials (**4-23** – **4-27**, Figure 6) using the previously described methodology with good isolated yields. These were then treated with K_2CO_3 under reflux in acetonitrile (36 h) to generate new cyclised compounds **14-1** – **14-5** (Figure 7). The structure of **14-2**, **14-3**, **14-5** was confirmed by X-ray analysis (see SI for X-ray data). To our knowledge, this type of oxazoline bridge head system has never been reported to date.

The isolated yields of these macrocyclic compounds can be rationalised by considering both the change in ring size (ring strain) and the increasing length of the linking tether in terms of the statistical likelihood of the cyclisation. Hence, due to the smaller ring size, **14-1**, a 10 membered ring, is a more strained structure (leads to a lower yield); whereas formation of the 15 membered ring, **14-5**, is kinetically less favoured, again resulting in a lower yield. Overall, this series of products represents a further intriguing structural diversification of the parent oxazolines **4** via very simple chemical manipulations.




Figure 7. Intramolecular cyclization products **14-1** – **14-5**.

Development of a Continuous Process

As these macrocyclic compounds were of particular interest as novel molecular entities, we wished to scale up their synthesis in order to access greater quantities of material for biological investigation. Therefore, the same intramolecular cyclizations were also attempted in flow where the enclosed reactor would allow higher reaction temperatures to be achieved to promote potentially faster reactions.¹⁷

The reactions were performed using a Vapourtec-E series flow reactor system¹⁸ fitted with a packed column reactor containing K_2CO_3 (Figure 8). The use of a back-pressure regulator (100 psi) allowed the reaction temperature to be increased to 130 °C without changing the solvent (acetonitrile). The reaction was carried out by directing a flow stream of the starting alkyl halide (**4-23** – **4-27**) stock solution at a concentration of 0.1 M through the packed column at rate of 400 $\mu L\ min^{-1}$. Notably under these conditions, equitable yields were obtained whilst reducing the reaction time from 36 h to 1.5 h. This enables easy access to gram quantities of the products with a productivity of 772 $mg\ h^{-1}$ (**14-3**, 72% yield), and the ability to produce 5 g in a standard 8 h working day even taking into account reactor set-up, priming, washing and shutdown.




Figure 8. Flow reactor set up used for scale up of products **14-1–14-5**.

CONCLUSION

We have shown a novel and general Ritter based cascade involving the condensation of a nitrile and a 3-hydroxyazetidine leading to the formation of new 2-oxazoline scaffolds. The cascade can also be exploited using other nucleophilic components such as phenols, which indicates additional bifunctional nucleophiles may also be viable. In addition, we have shown that specific alkyl bromide substituted 2-oxazolines prepared using this methodology can be further cyclised in an intramolecular process to create unique bicyclic heterocycles.

EXPERIMENTAL SECTION

General procedure for the rearrangement: To a solution of 3-hydroxyazetidine (3.15 mmol) in DCM (10 mL), was added 1 equiv. of H_2SO_4 dropwise, followed by 1 equiv. of nitrile (6 equiv. when the nitrile was acetonitrile) dissolved in DCM (3 mL). The reaction was refluxed and monitored by GC/LC-mass spectra. Upon complete disappearance of the starting material, the mixture was neutralised with an excess of sat. aq. Na_2CO_3 , and the mixture was extracted with EtOAc, washed with brine, dried over Na_2SO_4 , filtered and the solvent evaporated under reduced pressure. The resulting material was purified by chromatography column (typically with a mixture of hexane: EtOAc).

General flow procedure: A stock solution was prepared from the appropriate alkyl halide (2 mmol, **4-23** – **4-27**) are dissolved in acetonitrile (0.1 M). The solution was pumped at a flow rate of $400 \mu\text{L min}^{-1}$ through a 100×6.6 mm packed column reactor (4.10 mL) filled with K_2CO_3 and equipped with adjustable end pieces. A 100 psi back pressure regulator was added to the outlet line and the column reactor heated in the Vapourtec E2 column heater at 130°C . The acetonitrile was removed by evaporation, the residue was dissolved in EtOAc, washed with water, brine and dried over Na_2SO_4 . After evaporation the resulting material was purified by chromatography column (hexane EtOAc).

X-Ray crystals: The sample for X-ray analysis have been obtained by crystallization in EtOAc/Hexane

Starting materials for compounds **4-15**, **4-17** and **4-18** were available to this project having previously been synthesized in our group.¹⁹⁻²¹

3-chloro-1-[(4-methylphenyl)sulfonyl]-3-4phenyl-azetidine

Methanesulfonyl chloride (1.5 mL) was added, dropwise, to a solution of 3-(4-methyl)-1-tosylazetidin-3-ol (4.0 g) and N,N -diisopropylethylamine (3.5 mL) in DCM (100 mL) at 0°C . The mixture was stirred at 0°C for 7 hrs and then to room temperature overnight. The resulting mixture was washed with water and brine, dried over Na_2SO_4 and concentrated in vacuo.

IR ν = 1493 (m), 1330 (s), 1312 (s), 1185 (m), 1150 (s), 1049 (s), 1147 (s), 1090 (s), 813 (s), 829 (s), 675 (s); Melting point: $100\text{--}102^\circ\text{C}$ (crystallised from EtOAc: hexane); HR-MS: calculated for $\text{C}_{17}\text{H}_{19}\text{ClNO}_2\text{S}$ 336.0825, found 338.0831 ($\Delta = 0.6$ mDa).

4-methyl-*N*-[(2-methyl-4-phenyl-4,5-dihydrooxazol-4-yl)methyl]benzenesulfonamide (**4-1**).

Product obtained as Yellow oil (0.976 g, 90%). ^1H NMR (CDCl_3 , 400 MHz): δ 7.65 (d, $J = 8.3$ Hz, 2H), 7.32 – 7.18 (m, 9H), 5.53 (dd, $J = 9.1, 4.6$ Hz, 1H), 4.78 (d, 1H, $J = 8.5$ Hz), 4.31 (d, 1H, $J = 8.5$ Hz), 3.27 (dd, 1H, $J = 12.8, 9.1$ Hz), 3.02 (dd, 1H, $J = 12.8, 4.6$ Hz), 2.38 (s, 3H), 2.10 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 101 MHz): δ 167.3 (C), 143.8 (C), 143.5 (C), 137.0 (C), 129.8 (CH), 128.8 (CH), 127.7 (CH), 127.02 (CH), 125.5 (CH), 75.9 (C), 75.8 (CH₂), 51.7 (CH₂), 21.5 (CH₃), 14.1 (CH₃). IR: (neat) ν = 3282 (w), 1737 (m), 1696 (m), 1648 (m), 1359 (m), 1219 (m), 1211 (s), 1024 (m), 914 (m), 721 (m), 701 (m), 651 (m), 590 (s), 542 (s). HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{21}\text{N}_2\text{O}_3\text{S}$, 345.1273; found, 345.1281.

4-methyl-*N*-[(2-methyl-4-(*p*-tolyl)-4,5-dihydrooxazol-4-yl)methyl]benzenesulfonamide (**4-2**).

Product obtained as White solid (1.016 g, 90%). m.p. = $120\text{--}122^\circ\text{C}$. ^1H NMR (CDCl_3 , 400 MHz): δ 7.66 (d, 2H, $J = 8.0$ Hz), 7.19 (d, 2H, $J = 8.0$ Hz), 7.10 – 7.01 (m, 4H), 6.57 (dd, 1H, $J = 9.0, 4.8$ Hz), 4.84 (d, 1H, $J = 8.5$ Hz), 4.28 (d, 1H, $J = 8.5$ Hz), 3.28 (dd, 1H, $J = 13.2, 9.0$ Hz), 2.98 (dd, 1H, $J = 13.2, 4.8$ Hz), 2.38 (s, 3H), 2.30 (s, 3H), 2.11 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 101 MHz): δ 167.3 (C), 143.1 (C), 140.8 (C), 137.3 (C), 137.2 (C), 129.7 (CH), 129.3 (CH), 126.8 (CH), 125.3 (CH), 75.7 (CH₂), 75.8 (C), 51.1 (CH₂), 21.5 (CH₃), 20.7 (CH₃), 13.8 (CH₃). IR: (neat) ν = 3468 (w), 2961 (w), 1330 (s), 1180 (m), 1147 (s), 1088 (m), 814 (s), 677 (s), 516 (s). HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{23}\text{N}_2\text{O}_3\text{S}$, 359.1429; found, 359.1424.

4-methyl-*N*-[(2-methyl-4-(thiophen-2-yl)-4,5-dihydrooxazol-4-yl)methyl]benzenesulfonamide (**4-3**).

Product isolated via column chromatography (Hexane:EtOAc = 8:2 v/v) as Yellow oil (0.827 g, 75%). ^1H NMR (CDCl_3 , 400 MHz): δ 7.67 (d, 2H, $J = 8.4$ Hz), 7.23 (d, 2H, $J = 8.4$ Hz), 7.17 (dd, 1H, $J = 5.1, 1.2$ Hz), 6.93 (dd, 1H, $J = 5.1, 3.6$ Hz), 6.83 (dd, 1H, $J = 3.6, 1.2$ Hz), 5.86 (dd, 1H, $J = 9.0, 4.9$ Hz), 4.79 (d, 1H, $J = 8.6$ Hz), 4.37 (d, 1H, $J = 8.6$ Hz), 3.30 (dd, 1H, $J = 13.0, 9.0$ Hz), 3.15 (dd, 1H, $J = 13.0, 4.9$ Hz), 2.39 (s, 3H), 2.09 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 101

MHz): δ 168.2 (C), 147.6 (C), 143.5 (C), 137.0 (C), 129.8 (CH), 127.2 (CH), 127.0 (CH), 124.7 (CH), 122.8 (CH), 76.2 (CH₂), 74.0 (C), 51.1 (CH₂), 21.5 (CH₃), 13.9 (CH₃). IR: (neat) ν = 2923 (w), 1656 (m), 1327 (s), 1156 (s), 1089 (s), 813 (m), 752 (m), 659 (s), 549 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₆H₁₉N₂O₃S₂, 351.0837; found, 351.0825.

N-((4-([1,1'-biphenyl]-4-yl)-2-methyl-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (**4-4**).

Product isolated via column chromatography (Hexane:EtOAc = 7:3 v/v) as Pale Yellow oil (1.099 g, 83%). ¹H NMR (CDCl₃, 400 MHz): δ 7.68 (d, J = 8.3 Hz, 2H), 7.57 – 7.52 (m, 4H), 7.44 (t, 2H, J = 7.5 Hz), 7.38 – 7.34 (m, 3H), 7.24 (d, 2H, J = 8.2 Hz), 5.41 (s, 1H), 4.96 (d, 2H, J = 8.7 Hz), 4.49 (d, 2H, J = 8.7 Hz), 3.31 (dd, 1H, J = 13.1, 9.0 Hz), 3.17 (dd, 1H, J = 13.1, 4.9 Hz), 2.37 (s, 3H), 2.23 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 143.7 (C), 141.1 (C), 140.3 (C), 136.8 (C), 129.9 (CH), 129.8 (C), 128.9 (CH), 128.4 (C), 127.7 (CH), 127.1 (CH), 127.0 (CH), 127.0 (CH), 125.9 (CH), 77.0 (CH₂), 75.1 (C), 51.5 (CH₂), 21.6 (CH₃), 14.2 (CH₃). IR: (neat) ν = 2981 (w), 1744 (m), 1233 (m), 1158 (s), 1050 (m), 908 (m), 730 (s), 697 (m), 549 (m). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₄H₂₅N₂O₃S, 421.1586; found, 421.1581.

N-((4-(4-chlorophenyl)-2-propyl-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (**4-5**).

Product isolated via column chromatography (Hexane:EtOAc = 7:3 v/v) as Colourless oil (1.025 g, 80%). ¹H NMR (CDCl₃, 400 MHz): δ 7.62 (d, J = 8.4 Hz, 2H), 7.23 – 7.12 (m, 6H), 5.58 (dd, 1H, J = 8.5, 5.1 Hz), 4.69 (d, 1H, J = 8.6 Hz), 4.19 (d, 1H, J = 8.6 Hz), 3.22 (dd, 1H, J = 12.8, 8.5 Hz), 3.02 (dd, 1H, J = 12.8, 5.1 Hz), 2.37 (s, 3H), 2.40 – 2.22 (m, 2H), 1.66 (h, 2H, J = 7.0 Hz), 0.95 (t, 3H, J = 7.0 Hz). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 170.3 (C), 143.4 (C), 142.3 (C), 136.9 (C), 133.3 (C), 129.7 (CH), 128.7 (CH), 126.9 (CH), 126.8 (CH), 75.5 (CH₂), 75.3 (C), 51.5 (CH₂), 29.9 (CH₂), 21.5 (CH₃), 19.6 (CH₂), 13.7 (CH₃). IR: (neat) ν = 2930 (w), 1630 (m), 1337 (m), 1170 (s), 1097 (s), 811 (s), 648 (s), 553 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₀H₂₄ClN₂O₃S, 407.1184; found, 407.1196.

N-((2,4-di-*p*-tolyl-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (**4-6**).

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as white solid (1.190 g, 87%). ¹H NMR (CDCl₃, 400 MHz): δ 7.90 (d, 2H, J = 8.2 Hz), 7.66 (d, 2H, J = 8.2 Hz), 7.31 – 7.21 (m, 6H), 7.15 (d, 2H, J = 7.9 Hz), 4.96 (dd, 1H, J = 9.1, 4.5 Hz), 4.88 (d, 1H, J = 8.4 Hz), 4.46 (d, 1H, J = 8.4 Hz), 3.39 (dd, 1H, J = 12.6, 9.1 Hz), 3.22 (dd, 1H, J = 12.6, 4.5 Hz), 2.43 (s, 3H), 2.39 (s, 3H), 2.34 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 163.7 (C), 143.4 (C), 142.5 (C), 140.2 (C), 138.5 (C), 136.7 (C), 129.7 (CH), 129.46 (CH), 129.1 (CH), 128.7 (CH), 127.0 (CH), 125.5 (CH), 124.2 (C), 76.0 (CH₂), 75.7 (C), 51.7 (CH₂), 21.7 (CH₃), 21.5 (CH₃), 21.1 (CH₃). IR: (neat) ν = 2981 (w), 1639 (s), 1328 (s), 1158 (s), 1088 (s), 1075 (s), 891 (s), 658 (s), 547 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₅H₂₆N₂O₃S, 435.1742; found, 435.1737.

N-((4-(4-chlorophenyl)-2-(4-(trifluoromethyl)phenyl)-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (**4-7**).

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as colourless oil (1.077 g, 70%). ¹H NMR (CDCl₃, 400 MHz): δ 8.07 (d, 2H, J = 8.1 Hz), 7.62 (m, 4H), 7.24 (d, 2H, J = 8.1 Hz), 7.16 (m, 4H), 5.30 (dd, 1H, J = 9.4, 4.6 Hz), 4.95 (d, 1H, J = 8.5 Hz), 4.50 (d, 1H, J = 8.5 Hz), 3.37 (dd, 1H, J = 12.8, 9.4 Hz), 3.17 (dd, 1H, J = 12.8, 4.6 Hz), 2.37 (s, 3H), 2.32 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 164.0 (C), 143.6 (C), 140.5 (C), 137.7 (C), 136.7 (C), 133.5 (q, J = 32.5 Hz, C), 130.5 (C), 129.8 (CH), 129.62 (CH), 129.1 (CH), 127.0 (q, J = 207.1 Hz, C), 127.0 (CH), 125.4 (q, J = 3.81 Hz, CH), 76.3 (CH), 76.2 (C), 51.9 (CH₂), 21.6 (CH₃), 21.16 (CH₃). IR (neat) ν = 3267 (w), 2982 (w), 1649 (m), 1321 (s), 1160 (s), 1073 (s), 1090 (s), 853 (m), 730 (s), 510 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₅H₂₄F₃N₂O₃S, 489.1503; found, 489.1505.

N-((2-(3-cyanophenyl)-4-(*p*-tolyl)-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (**4-8**).

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as white solid (0.491 g, 35%). m.p. = 217–220 °C. ¹H NMR (DMSO-*d*₆, 400 MHz): δ 8.15 (d, 1H, J = 8.3 Hz), 7.84 (t, 1H, J = 6.9 Hz), 7.67 (d, 3H, J = 7.7 Hz), 7.30 (d, 5H, J = 7.7 Hz), 7.15 (d, 2H, J = 7.7 Hz), 4.97 (d, 1H, J = 8.4 Hz), 4.44 (d, 1H, J = 8.4 Hz), 3.13 (dd, 1H, J = 13.4, 7.9 Hz), 2.98 (dd, 1H, J = 13.4, 5.9 Hz), 2.30 (s, 3H), 2.25 (s, 3H). ¹³C{¹H} NMR (DMSO-*d*₆, 101 MHz): δ 162.2 (C), 142.6 (C), 141.0 (C), 137.7 (C), 136.8 (CH), 136.5 (C), 136.1 (CH), 131.3 (CH), 130.7 (CH), 129.5 (CH), 129.1 (CH), 127.6 (C), 126.5 (CH), 125.7 (CH), 117.2 (C), 112.8 (C), 76.4 (C), 75.1 (CH₂), 52.1 (CH₂), 20.9 (CH₃), 20.6 (CH₃). IR (neat) ν = 2979 (w), 1633 (m), 1591 (s), 1328 (m), 1156 (s), 1088 (s), 1071 (m), 810 (s), 703 (m), 659 (s), 562 (m), 548 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₅H₂₄N₃O₃S, 446.1538; found, 446.1530.

N-((2-(4-(2-bromoacetyl)phenyl)-4-(4-chlorophenyl)-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (**4-9**).

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as pale yellow crystals (1.203 g, 68%). m.p. = 120–122 °C. ¹H NMR (CDCl₃, 400 MHz): δ 8.04 (d, 2H, J = 8.0 Hz), 7.95 (d, 2H, J = 8.0 Hz), 7.58 (d, 2H, J = 7.9 Hz), 7.19 (d, 2H, J = 7.9 Hz), 5.18 (dd, 2H, J = 8.7, 5.0 Hz), 4.90 (d, 2H, J = 8.7 Hz), 4.43 (m, 3H), 3.31 (dd, 1H, J = 12.8, 8.7 Hz), 3.17 (dd, 1H, J = 12.8, 5.0 Hz), 2.37 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 191.6 (C), 164.2 (C), 143.7 (C), 141.9 (C), 136.6 (C), 136.3 (C), 133.8 (C), 131.6 (C), 129.8 (CH), 129.1 (CH), 128.9 (CH), 128.9 (CH), 127.1 (CH), 126.9 (CH), 76.2 (CH₂), 76.1 (C), 49.8 (CH₂), 30.8 (CH₂), 22.7 (CH₃). IR (neat) ν = 3302 (w), 1694 (m), 1642 (m), 1312 (m), 1151 (s), 1088 (s), 834 (s), 814 (s), 654 (s), 546 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₅H₂₃N₂O₄⁷⁹BrS³⁵Cl, 561.0250; found, 561.0236.

N-((4-(4-chlorophenyl)-2-(4-(2-(methyl(phenyl)amino)ethyl)phenyl)-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (**4-10**).

Product isolated via column chromatography (eluent Hexane:EtOAc = 8:2 v/v) as Yellow oil (1.204 g, 65%). ¹H

NMR (CDCl₃, 700 MHz): δ 8.09 (d, 2H, J = 8.4 Hz), 8.01 (d, 2H, J = 8.4 Hz), 7.62 (d, 2H, J = 8.3 Hz), 7.29 (s, 4H), 7.25 – 7.20 (m, 4H), 6.75 (tt, 1H, J = 7.6, 1.0 Hz), 6.69 (d, 2H, J = 7.6 Hz), 4.91 (d, 1H, J = 8.4 Hz), 4.81 – 4.78 (m, 3H), 4.47 (d, 1H, J = 8.4 Hz), 3.34 (dd, 1H, J = 12.8, 8.6 Hz), 3.21 (dd, 1H, J = 12.8, 5.1 Hz), 3.11 (s, 3H), 2.40 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 176 MHz): δ 196.4 (C), 164.4 (C), 149.1 (C), 143.8 (C), 141.9 (C), 138.0 (C), 136.8 (C), 133.9 (C), 131.3 (C), 129.9 (CH), 129.4 (CH), 129.2 (CH), 129.0 (CH), 127.9 (CH), 127.2 (CH), 127.0 (CH), 117.5 (CH), 112.5 (CH), 76.2 (C), 76.2 (CH₂), 59.4 (CH₂), 51.9 (CH₂), 39.7 (CH₃), 21.6 (CH₃). IR: (neat) ν = 1697 (s), 1647 (m), 1331 (m), 1159 (s), 1089 (s), 812 (m), 744 (m), 660 (m), 546 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₃₂H₃₁N₃O₄S³⁵Cl, 588.1724; found, 588.1714.

N-((2-(1H-pyrrol-2-yl)-4-(*p*-tolyl)-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (**4-11**).

Product isolated via column chromatography (eluent Hexane:EtOAc = 8:2 v/v as Yellow oil (0.748 g, 58%). ¹H NMR (CDCl₃, 400 MHz): δ 10.02 (s, 1H), 7.53 (d, 2H, J = 8.0 Hz), 7.16 (d, 2H, J = 8.0 Hz), 7.08 (d, 2H, J = 8.0 Hz), 7.05 – 6.95 (m, 3H), 6.50 (s, 1H), 6.16 (s, 1H), 4.91 (d, 1H, J = 8.4 Hz), 4.28 (d, 1H, J = 8.4 Hz), 3.54 (dd, 1H, J = 13.4, 9.6 Hz), 3.03 (dd, 1H, J = 13.4, 4.0 Hz), 2.32 (ap. s, 6H). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 160.8 (C), 143.2 (C), 141.0 (C), 137.5 (C), 136.9 (C), 129.7 (CH), 129.5 (CH), 126.8 (CH), 125.5 (CH), 123.0 (CH), 118.6 (C), 114.7 (CH), 110.1 (CH), 75.9 (CH₂), 75.3 (C), 52.6 (CH₂), 21.5 (CH₃), 21.1 (CH₃). IR: (neat) ν = 3333 (w), 1640 (s), 1429 (m), 1307 (m), 1155 (s), 1087 (m), 985 (m), 813 (s), 738 (s), 660 (s), 547(s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₂H₂₄N₃O₃S, 410.1538; found 410.1542.

1-((4-(4-chlorophenyl)-4-((4-methylphenylsulfonamido)methyl)-4,5-dihydrooxazol-2-yl)methyl)pyridin-1-ium salt (**4-12**).

Product isolated by crystallization from Hexane:EtOAc as white solid (0.547 g, 38%). m.p. = 227-230 °C. ¹H NMR (CD₃OD, 400 MHz): δ 8.92 (d, 2H, J = 6.0 Hz), 8.64 (t, 1H, J = 7.9 Hz), 8.14 (t, 2H, J = 7.0 Hz), 7.70 (d, 2H, J = 7.9 Hz), 7.35 (m, 6H), 5.62 (s, 2H), 3.98 (d, 1H, J = 11.1 Hz), 3.88 (d, 1H, J = 11.1 Hz), 3.55 (q, 1H, J = 13.8 Hz), 2.44 (s, 3H). ¹³C{¹H} NMR (CD₃OD, 101 MHz): δ 156.2 (C), 138.1 (CH), 138.0 (CH), 135.4 (C), 130.5 (C), 129.1(C), 124.5(C), 121.3 (CH), 119.8 (CH), 119.5 (CH), 119.3 (CH), 118.5 (CH), 56.6 (CH₂), 54.7 (C), 53.9 (CH₂), 36.3 (CH₂), 11.9 (CH₃). IR: (neat) ν = 2982 (w), 1700 (m), 1493 (m), 1154 (s), 1010 (s), 548 (s). HRMS (ESI) m/z : [M + H₂O]⁺ calcd for C₂₃H₂₅N₃O₄S³⁵Cl, 474.1254; found, 474.1247.

4-methyl-*N*-((2-(thiophen-2-yl)-4-(*p*-tolyl)-4,5-dihydrooxazol-4-yl)methyl)benzenesulfonamide (**4-13**).

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as yellow oil (1.048 g, 78%). m.p. = 130-133 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.65 (m, 3H), 7.50 (d, J = 5.0 Hz, 1H), 7.29 – 7.19 (m, 4H), 7.19 – 7.07 (m, 3H), 4.87 (d, 2H, J = 8.3 Hz), 4.46 (d, 1H, J = 8.3 Hz), 3.37 (dd, 1H, J = 12.6, 9.3 Hz), 3.17 (dd, 1H, J = 12.6, 4.4 Hz), 2.38 (s, 3H), 2.32 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 161.0 (C), 143.5 (C), 140.7 (C), 137.5 (C), 136.7 (C), 131.5 (CH), 130.7 (CH), 129.8 (CH), 129.5 (C), 129.5 (CH), 127.8 (CH), 127.0 (CH), 125.5 (CH), 76.4 (CH₂), 76.1 (C), 51.6

(CH₂), 21.6 (CH₃), 21.1 (CH₃). IR: (neat) ν = 3056 (w), 1635 (s), 1326 (s), 1159 (s), 1084 (s), 813 (s), 727 (s), 714 (s), 659 (s), 548 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₂H₂₃N₂O₃S₂, 427.1107; found, 427.1112.

4-methyl-*N*-((2-(thiophen-2-ylmethyl)-4-(*p*-tolyl)-4,5-dihydrooxazol-4-yl)methyl)benzenesulfonamide (**4-14**).

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as yellow oil (1.054 g, 76%). ¹H NMR (CDCl₃, 400 MHz): δ 7.63 (d, 2H, J = 8.4 Hz), 7.29 (dd, 1H, J = 5.0, 3.0 Hz), 7.24 – 7.19 (m, 3H), 7.13 – 7.05 (m, 5H), 5.34 (dd, 1H, J = 9.1, 4.7 Hz), 4.80 (d, 1H, J = 8.5 Hz), 4.31 (d, 1H, J = 8.5 Hz), 3.84 – 3.66 (m, 2H), 3.27 (dd, 1H, J = 12.8, 9.1 Hz), 3.04 (dd, 1H, J = 12.8, 4.7 Hz), 2.39 (s, 3H), 2.31 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 168.1 (C), 143.4 (C), 140. (C), 137.4 (C), 137.0 (C), 134.4 (C), 129.8 (CH), 129.4 (CH), 128.3 (CH), 126.9 (CH), 126.1 (CH), 125.38 (CH), 122.8 (CH), 76.2 (CH₂), 75.6 (C), 51.7 (CH₂), 29.4 (CH₂), 21.5 (CH₃), 21.0 (CH₃). IR: (neat) ν = 1649 (s), 1418 (m), 1326 (s), 1161 (s), 1088 (s), 811 (s), 751 (s), 662 (s), 559 (s), 550 (s), 540 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₃H₂₅N₂O₃S₂, 441.1307; found, 441.1321.

N-((2-(5-amino-1-(2,5-dichlorophenyl)-1H-pyrazol-3-yl)-4-(4-chlorophenyl)-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (**4-15**).

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as white solid (1.060 g, 57%). m.p. = 91-93 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.67 (s, 1H), 7.61 (d, 2H, J = 8.3 Hz), 7.53 – 7.46 (m, 2H), 7.42 (dd, 2H, J = 8.6, 2.5 Hz), 7.27 – 7.18 (m, 6H), 5.36 (s, 2H), 5.28 (m, 1H), 4.63 (d, 1H, J = 8.4 Hz), 4.27 (d, 1H, J = 8.4 Hz), 3.26 (dd, 1H, J = 12.3, 7.7 Hz), 3.16 (dd, 1H, J = 12.3, 5.4 Hz), 2.40 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 161.5 (C), 149.1 (C), 143.6 (C), 143.6 (C), 142.4 (C), 140.2 (CH), 136.5 (C), 135.8 (C), 133.72 (C), 133.4 (C), 131.6 (CH), 131.1 (CH), 130.4 (C), 130.1 (CH), 129.8 (CH), 128.8 (CH), 127.2 (CH), 127.0 (CH), 75.2 (C), 75.1 (CH₂), 52.1 (CH₂), 21.6 (CH₃). IR: (neat) ν = 3278 (w), 1643 (s), 1616 (s), 1157 (s), 1090 (s), 811 (s), 661 (s), 552 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₆H₂₃N₅O₃S³⁵Cl₃, 590.0587; found, 590.0595.

N-((4-(4-chlorophenyl)-2-(7-hydroxy-4-methyl-2-oxo-2H-chromen-3-yl)-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (**4-16**).

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as yellow oil (0.713 g, 42%). ¹H NMR (CDCl₃, 400 MHz): δ 7.76 (d, 2H, J = 7.9 Hz), 7.43 (d, 1H, J = 8.8 Hz), 7.33 – 7.27 (m, 6H), 6.88 (dd, 1H, J = 8.8, 2.2 Hz), 6.75 – 6.63 (m, 2H), 5.13 (d, 1H, J = 8.7 Hz), 4.45 (d, 1H, J = 8.7 Hz), 3.50 – 3.38 (m, 1H), 3.08 (d, 1H, J = 12.3 Hz), 2.40 (d, 6H, J = 7.2 Hz). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 162.9 (C), 160.5 (C), 154.7 (C), 143.7 (C), 143.6 (C), 138.83 (C), 136.2 (C), 133.7 (C), 130.0 (CH), 129.7 (CH), 129.3 (CH), 127.3 (CH), 127.1 (CH), 126.9 (CH), 126.4 (CH), 114.9 (C), 111.8 (C), 102.1 (C), 76.3 (C), 76.2 (CH₂), 52.0 (CH₂), 21.2 (CH₃), 17.8 (CH₃). IR: (neat) ν = 3453 (m, OH), 1595 (w), 1330 (s), 1182 (s), 1147 (s), 1088 (s), 909 (m), 815 (s), 675 (s), 603 (s), 562 (s), 515 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₇H₂₄N₂O₆S³⁵Cl, 539.1044; found, 539.1036.

N-((4-(4-chlorophenyl)-2-(1-(4-nitrophenyl)-1*H*-1,2,3-triazol-4-yl)-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (**4-17**).

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as yellow oil (0.939 g, 56%). ¹H NMR (CDCl₃, 400 MHz): δ 9.01 (s, 1H), δ 8.48 (d, 2H, *J* = 9.0 Hz), 8.10 (d, 2H, *J* = 9.0 Hz), 7.59 (d, 2H, *J* = 8.3 Hz), 7.19 – 7.13 (m, 4H), 7.08 (d, 2H, *J* = 8.0 Hz), 6.39 (s, 1H), 5.14 (d, 2H, *J* = 8.6 Hz), 4.49 (d, 2H, *J* = 8.6 Hz), 3.49 (dd, 1H, *J* = 13.4, 9.4 Hz), 3.15 (dd, 1H, *J* = 13.4, 4.6 Hz), 2.32 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 158.7 (C), 147.8 (C), 143.6 (C), 140.7 (C), 140.0 (C), 137.9 (C), 137.7 (C), 137.1 (C), 129.9 (CH), 129.7 (CH), 126.8 (CH), 125.8 (CH), 125.4 (CH), 124.6 (CH), 121.2 (CH), 42.1 (CH₂), 27.1 (CH₂), 25.1 (C), 21.6 (CH₃), 21.1 (CH₃). IR: (neat) ν = 1487 (m), 1202 (m), 1157 (m), 904 (s), 728 (s). HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₆H₂₅N₆O₅S, 533.1607; found, 533.1590.

4-(4-(4-chlorophenyl)-4-((4-methylphenylsulfonamido)methyl)-4,5-dihydrooxazol-2-yl)-4-(2-hydroxy-2-methylpropyl)-3,3-dimethylcyclohex-1-enecarboxylic acid (**4-18**).

Product obtained by crystallization from Hexane EtOAc as white solid (1.503 g, 81%). m.p. = 88–90 °C. ¹H NMR (CDCl₃, 600 MHz): δ 7.61 (d, 2H, *J* = 8.3 Hz), 7.32 – 7.29 (m, 2H), 7.24 – 7.19 (m, 4H), 6.62 (dt, 1H, *J* = 14.4, 1.8 Hz), 5.59 (m, 1H), 4.35 – 4.26 (m, 2H), 3.37 (dd, 1H, *J* = 13.4, 7.1 Hz), 3.17 (dd, 1H, *J* = 13.4, 4.7 Hz), 2.39 (s, 3H), 2.37 – 2.33 (m, 1H), 2.33 – 2.24 (m, 1H), 2.20 (d, 1H, *J* = 13.5 Hz), 2.06 – 1.99 (m, 1H), 1.88 (dddd, 1H, *J* = 13.9, 10.1, 6.2, 3.3 Hz), 1.75 (d, 1H, *J* = 13.5 Hz), 1.42 (s, 3H), 1.38 (s, 3H), 1.10 (s, 3H), 0.98 (d, 3H, *J* = 2.5 Hz). ¹³C{¹H} NMR (CDCl₃, 151 MHz): δ 166.7 (C), 148.0 (CH), 143.5 (C), 139.7 (C), 136.6 (C), 133.7 (C), 129.7 (CH), 128.4 (CH), 127.3 (C), 127.2 (CH), 127.1 (CH), 81.5 (C), 74.6 (C), 69.2 (CH₂), 50.4 (C), 50.1 (CH₂), 45.7 (CH₂), 37.2 (C), 30.5 (CH₃), 30.0 (CH₂), 29.90 (CH₃), 29.36 (C), 26.26 (CH₃), 23.06 (CH₃), 21.7 (CH₂), 21.61 (CH₃). IR: (neat) ν = 2986 (w), 1711 (m), 1654 (m), 1248 (s), 1156 (s), 1090 (s), 1046 (m), 814 (m), 660 (s), 549 (s). HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₀H₃₈N₂O₆S³⁵Cl, 589.2139; found, 589.2136.

N,N'-(((meso)-2,2'-(propane-1,3-diyl)bis(4-phenyl-4,5-dihydrooxazole-4,2-diyl))bis(methylene))bis(4-methylbenzenesulfonamide) (**4-20**)

Product isolated via column chromatography (eluent Hexane:EtOAc = 8:2 v/v) as white solid (0.441 g, 20%). ¹H NMR (C₂D₆OS, 400 MHz): δ 7.66 (d, 6H, *J* = 7.9 Hz), 7.35 – 7.28 (m, 12H), 7.25 (m, 2H), 4.69 (d, 2H, *J* = 8.6 Hz), 4.19 (d, 2H, *J* = 8.6 Hz), 3.38 (s, 6H), 2.99 (dd, 2H, *J* = 13.1, 7.9 Hz), 2.82 (dd, 2H, *J* = 13.1, 5.8 Hz), 2.46 – 2.38 (m, 4H), 2.04 – 1.90 (m, 2H). ¹³C{¹H} NMR (C₂D₆OS, 101 MHz): δ 167.0 (C), 144.2 (C), 142.6 (C), 137.7 (C), 129.6 (CH), 128.4 (CH), 127.2 (CH), 126.5 (CH), 125.8 (CH), 75.9 (C), 74.4 (CH₂), 52.0 (CH₂), 26.7 (CH₂), 21.9 (CH₂), 20.9 (CH₃). IR: (neat) ν = 3338 (w), 2971 (w), 1742 (w), 1663 (w), 1333 (m), 1157 (s), 1131 (m), 1092 (m), 818 (m), 700 (s), 664 (s), 543 (s). HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₇H₄₁N₄O₆S₂, 701.2468; found, 701.2480.

N,N'-(((Rac)-2,2'-(propane-1,3-diyl)bis(4-phenyl-4,5-dihydrooxazole-4,2-diyl))bis(methylene))bis(4-methylbenzenesulfonamide) (**4-21**)

Product isolated via column chromatography (eluent Hexane:EtOAc = 8:2 v/v) as white solid (0.441 g, 20%). ¹H NMR (CDCl₃, 400 MHz): δ 9.17 (dd, 2H, *J* = 10.2, 3.7 Hz), 7.56 (d, 4H, *J* = 8.0 Hz), 7.29 (s, 10H), 7.01 (d, 4H, *J* = 8.0 Hz), 5.10 (d, 2H, *J* = 8.6 Hz), 4.29 (d, 2H, *J* = 8.6 Hz), 3.47 (dd, 1H, *J* = 13.7, 10.2 Hz), 3.11 (ddd, 2H, *J* = 15.0, 10.0, 8.7 Hz), 2.82 (dd, 1H, *J* = 13.7, 3.7 Hz), 2.59 (dt, 2H, *J* = 15.0, 4.5 Hz), 2.30 (s, 6H), 2.08 (td, 2H, *J* = 10.0, 8.6, 4.5 Hz). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 170.4 (C), 143.6 (C), 142.8 (C), 138.6 (C), 129.6 (CH), 128.9 (CH), 127.8 (CH), 126.2 (CH), 124.6 (CH), 76.3 (CH₂), 76.0 (C), 50.8 (CH₂), 24.6 (CH₂), 20.9 (CH₃), 19.3 (CH₂). IR (neat) ν = 3062 (w), 2870 (w), 1164 (s), 1147 (w), 1130 (s), 1158 (s), 1091 (s), 1010 (s), 912 (m), 723 (m), 764 (s), 554 (s). HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₇H₄₁N₄O₆S₂, 701.2468; found, 701.2474.

N-((2-(3-cyanopropyl)-4-phenyl-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (**4-22**)

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as colourless oil (0.265 g, 22%). ¹H NMR (CDCl₃, 400 MHz): δ 7.67 (d, 2H, *J* = 8.1 Hz), 7.36 – 7.30 (m, 2H), 7.30 – 7.18 (m, 5H), 5.21 (dd, 1H, *J* = 8.9, 5.0 Hz), 4.86 (d, 1H, *J* = 8.6 Hz), 4.39 (d, 1H, *J* = 8.6 Hz), 3.24 (dd, 1H, *J* = 13.0, 8.9 Hz), 3.10 (dd, 1H, *J* = 13.0, 5.0 Hz), 2.60 (t, 2H, *J* = 7.1 Hz), 2.53 (t, 2H, *J* = 7.1 Hz), 2.39 (s, 3H), 2.09 (p, 2H, *J* = 7.1 Hz). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 167.5 (C), 143.7 (C), 142.5 (C), 136.4 (C), 129.9 (CH), 129.0 (CH), 128.0 (CH), 127.0 (CH), 125.5 (CH), 119.2 (C), 76.3 (CH₂), 75.7 (C), 49.4 (CH₂), 27.2 (CH₂), 21.7 (CH₂), 21.6 (CH₃), 16.7 (CH₂). IR: (neat) ν = 3263 (w), 2177 (w), 1663 (w), 1327 (w), 1160 (s), 1091 (m), 906 (s), 727 (s), 702 (s), 551 (s). HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₀H₂₂N₃O₃S, 384.1338; found, 384.1335.

N-((4-methoxy-2-(*p*-tolyl)-2,3-dihydrobenzofuran-2-yl)methyl)-4-methylbenzenesulfonamide (**7**).

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as white solid (0.533 g, 40%). ¹H NMR (CDCl₃, 400 MHz): δ 7.65 (d, 2H, *J* = 8.2 Hz), 7.28 (d, 2H, *J* = 8.2 Hz), 7.11 (d, 2H, *J* = 8.2 Hz), 7.05 (d, 2H, *J* = 8.4 Hz), 6.89 (d, 1H, *J* = 8.7 Hz), 6.44 (d, 1H, *J* = 6.5 Hz), 4.71 (d, 1H, *J* = 9.0 Hz), 4.51 (d, 1H, *J* = 9.0 Hz), 4.26 (dd, 1H, *J* = 8.5, 4.5 Hz), 3.79 (s, 3H), 3.55 (dd, 1H, *J* = 12.2, 8.5 Hz), 3.35 (dd, 1H, *J* = 12.2, 4.5 Hz), 2.43 (s, 3H), 2.31 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 162.1 (C), 161.5 (C), 143.7 (C), 139.5 (C), 137.2 (C), 136.5 (C), 129.9 (CH), 129.7 (CH), 127.1 (CH), 126.4 (CH), 125.0 (CH), 120.9 (C), 107.2 (CH), 96.7 (CH), 82.3 (CH₂), 55.6 (CH₃), 53.3 (C), 49.9 (CH₂), 21.6 (CH₃), 21.0 (CH₃). IR: (neat) ν = 3263 (w), 1621 (w), 1326 (m), 1156 (s), 1091 (m), 804 (m), 661 (m), 549 (s). HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₄H₂₆NO₄S, 424.1583; found, 424.1583.

N-((5-methoxy-2-phenyl-2,3-dihydrobenzofuran-2-yl)methyl)-4-methylbenzenesulfonamide (**8**)

Product obtained by crystallization (Hexane:EtOAc) as white crystals (0.580 g, 45%). ¹H NMR (CDCl₃, 400 MHz): δ 7.64 (d, 2H, *J* = 8.2 Hz), 7.33 – 7.18 (m, 7H), 6.77 – 6.70 (m, 2H), 6.59 (dd, 1H, *J* = 2.3, 0.8 Hz), 4.70 (d, 1H, *J* = 9.1 Hz), 4.64 (dd, 1H, *J* = 8.6, 5.4 Hz), 4.52 (d, 1H, *J* = 9.1 Hz), 3.69 (s, 3H), 3.61 (dd, 1H, *J* = 12.5, 8.6 Hz), 3.43 (dd, 1H, *J* = 12.5, 5.4 Hz), 2.41 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 154.6 (C), 154.3 (C), 143.6 (C), 141.5 (C), 136.0 (C), 130.0

(C), 129.8 (CH), 128.9 (CH), 127.4 (CH), 127.0 (CH), 126.5 (CH), 114.5 (CH), 110.8 (CH), 110.5 (CH), 80.9 (CH₂), 55.9 (CH₃), 54.4 (C), 49.3 (CH₂), 20.5 (CH₃). IR (neat) ν = 3270 (w), 2254 (w), 1489 (m), 1160 (m), 904 (s), 723 (s), 648 (s), 661 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₃H₂₄NO₄S, 410.1426; found, 410.1445.

3-((4-methoxyphenyl)thio)-3-(*p*-tolyl)-1-tosylazetidine (9).

Product obtained by crystallization (Hex: EtOAc = 1:1 v/v) as brown solid (0.969 g, 70%). m.p. = 124–126 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.63 (d, 2H, J = 8.3 Hz), 7.28 – 7.22 (m, 2H), 7.06 – 6.99 (m, 4H), 6.76 (d, 2H, J = 8.2 Hz), 6.71 (d, 2H, J = 8.8 Hz), 4.24 (d, 2H, J = 8.3 Hz), 4.13 (d, 2H, J = 8.3 Hz), 3.78 (s, 3H), 2.40 (s, 3H), 2.30 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 160.8 (C), 144.1 (C), 139.1 (C), 138.0 (CH), 137.0 (C), 132.2 (C), 129.7 (CH), 128.9 (CH), 128.2 (CH), 126.1 (CH), 121.9 (C), 114.3 (CH), 61.7 (CH₂), 55.3 (CH₃), 49.3 (C), 21.6 (CH₃), 21.1 (CH₃). IR: (neat) ν = 2980 (w), 1588 (m), 1465 (m), 1344 (m), 1158 (s), 1037 (m), 813 (m), 725 (s), 673 (s), 548 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₄H₂₆NO₃S₂, 440.1354; found, 440.1342.

3-((3-methoxyphenyl)thio)-3-(*p*-tolyl)-1-tosylazetidine (10).

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as orange oil (1.177 g, 85%). ¹H NMR (CDCl₃, 400 MHz): δ 7.66 (d, 2H, J = 8.3 Hz), 7.27 (d, 2H, J = 7.7 Hz), 7.09 (dd, 1H, J = 8.4, 7.6 Hz), 7.02 (d, 2H, J = 7.7 Hz), 6.87 – 6.79 (m, 3H), 6.72 (ddd, 1H, J = 7.6, 1.6, 1.0 Hz), 6.48 (dd, 1H, J = 1.6, 1.0 Hz), 4.26 (d, 2H, J = 8.4 Hz), 4.15 (d, 2H, J = 8.4 Hz), 3.60 (s, 3H), 2.40 (s, 3H), 2.29 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 159.3 (C), 144.2 (C), 138.9 (C), 137.1 (C), 132.3 (C), 131.8 (C), 129.7 (CH), 129.5 (CH), 128.9 (CH), 128.2 (CH), 127.6 (CH), 126.2 (CH), 119.8 (CH), 115.6 (CH), 62.1 (CH₂), 55.1 (CH₃), 49.1 (C), 21.6 (CH₃), 21.0 (CH₃). IR: (neat) ν = 2980 (w), 1587 (m), 1346 (m), 1157 (s), 908 (m), 813 (m), 725 (s), 672 (s), 548 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₄H₂₆NO₃S₂, 440.1357; found, 440.1346.

***N*-(2-(4-bromophenyl)-2-oxoethyl)-4-methyl-*N*-((2-methyl-4-(*p*-tolyl)-4,5-dihydrooxazol-4-yl)methyl)benzenesulfonamide (11).**

Product isolated as Yellow oil (0.649 g, 60%). ¹H NMR (400 MHz, CDCl₃): δ 7.64 (d, 2H, J = 8.6 Hz), 7.61 (d, 2H, J = 8.3 Hz), 7.57 (d, 2H, J = 8.4 Hz), 7.33 – 7.31 (m, 4H), 7.24 (d, 2H, J = 8.4 Hz), 4.98 (d, 1H, J = 8.7 Hz), 4.88 – 4.70 (m, 2H), 4.33 (d, 1H, J = 8.7 Hz), 3.83 (d, 1H, J = 14.8 Hz), 3.61 (d, 1H, J = 14.8 Hz), 2.40 (s, 3H), 1.86 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 192.7 (C), 166.3 (C), 144.1 (C), 143.6 (C), 136.5 (C), 134.0 (C), 132.1 (CH), 129.7 (CH), 129.34 (CH), 128.7 (CH), 128.7 (C), 127.6 (CH), 127.6 (CH), 125.8 (CH), 77.0 (C), 76.1 (CH₂), 56.5 (CH₂), 54.5 (CH₂), 21.6 (CH₃), 14.1 (CH₃). IR: (neat) ν = 2924 (w), 1672 (m), 1585 (m), 1334 (m), 1156 (s), 982 (s), 908 (s), 729 (s), 547 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₆H₂₆N₂O₄S⁷⁹Br, 541.0797; found, 541.0780.

***N*-((2-(5-bromopentyl)-4-(*p*-tolyl)-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (4-23).**

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as colourless oil (1.088 g, 70%).

¹H NMR (CDCl₃, 400 MHz): δ 7.65 (d, 2H, J = 8.0 Hz), 7.23 (d, 2H, J = 8.0 Hz), 7.16 – 7.06 (m, 4H), 5.02 (dd, 1H, J = 9.3, 4.6 Hz), 4.72 (d, 1H, J = 8.5 Hz), 4.28 (d, 1H, J = 8.5 Hz), 3.41 (t, 2H, J = 6.7 Hz), 3.24 (dd, 1H, J = 12.6, 9.3 Hz), 3.04 (dd, 1H, J = 12.6, 4.6 Hz), 2.39 (s, 3H), 2.31 (s, 3H), 1.94 – 1.83 (m, 2H), 1.78 – 1.62 (m, 2H), 1.52 (ddd, 2H, J = 10.2, 8.4, 4.8 Hz). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 169.8 (C), 143.5 (C), 140.8 (C), 137.4 (C), 136.8 (C), 129.9 (CH), 129.4 (CH), 127.0 (CH), 125.4 (CH), 75.8 (CH₂), 75.0 (C), 51.7 (CH₂), 33.7 (CH₂), 32.3 (CH₂), 28.5 (CH₂), 27.0 (CH₂), 25.3 (CH₂), 22.3 (CH₃), 21.0 (CH₃). IR: (neat) ν = 3089 (w), 2868 (w), 1651 (m), 1333 (s), 1160 (s), 1089 (s), 811 (s), 659 (m), 554 (s), 545 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₃H₃₀⁷⁹BrN₂O₃S, 493.1161; found, 493.1146.

***N*-((2-(6-bromohexyl)-4-(4-chlorophenyl)-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (4-24).**

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as colourless oil (1.247 g, 75%). ¹H NMR (CDCl₃, 400 MHz): δ 7.62 (d, 2H, J = 8.2 Hz), 7.20 (m, 4H), 7.15 (d, 2H, J = 8.7 Hz), 5.44 (dd, 1H, J = 8.7, 5.0 Hz), 4.68 (d, 1H, J = 8.6 Hz), 4.20 (d, 1H, J = 8.6 Hz), 3.37 (t, 2H, J = 7.0 Hz), 3.21 (dd, 1H, J = 12.8, 8.7 Hz), 3.01 (dd, 1H, J = 12.8, 5.0 Hz), 2.37 (s, 3H), 2.35 – 2.24 (m, 2H), 1.83 (p, 2H, J = 7.0 Hz), 1.64 (p, 2H, J = 7.0 Hz), 1.52 – 1.28 (m, 4H). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 170.2 (C), 143.5 (C), 142.3 (C), 137.2 (C), 133.4 (C), 130.0 (CH), 129.7 (CH), 126.9 (CH), 126.8 (CH), 75.5 (CH₂), 75.3 (C), 51.5 (CH₂), 33.9 (CH₂), 32.4 (CH₂), 28.2 (CH₂), 27.9 (CH₂), 27.7 (CH₂), 25.8 (CH₂), 21.5 (CH₃). IR: (neat) ν = 2932 (w), 1658 (m), 1328 (m), 1157 (s), 1090 (s), 813 (s), 661 (s), 548 (s). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₃H₂₉⁷⁹Br³⁵ClN₂O₃S, 527.0736; found, 527.0743.

***N*-((2-(7-bromoheptyl)-4-(*p*-tolyl)-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (4-26).**

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as colourless oil (1.232 g, 75%). ¹H NMR (CDCl₃, 400 MHz): δ 7.65 (d, 2H, J = 8.1 Hz), 7.22 (d, 2H, J = 8.1 Hz), 7.15 – 7.05 (m, 4H), 5.26 (dd, 1H, J = 9.2, 4.6 Hz), 4.72 (d, 1H, J = 8.4 Hz), 4.27 (d, 1H, J = 8.4 Hz), 3.39 (t, 2H, J = 6.8 Hz), 3.25 (dd, 1H, J = 12.7, 9.2 Hz), 3.01 (dd, 1H, J = 12.7, 4.6 Hz), 2.43 – 2.30 (m, 2H), 2.38 (s, 3H), 2.30 (s, 3H), 1.84 (p, J = 6.9 Hz, 2H), 1.71 – 1.62 (m, 2H), 1.49 – 1.28 (m, 6H). ¹³C{¹H} NMR (CDCl₃, 101 MHz): δ 170.1 (C), 143.4 (C), 140.9 (C), 137.3 (C), 136.8 (C), 129.7 (CH), 129.4 (CH), 126.9 (CH), 125.3 (CH), 75.7 (CH₂), 75.3 (C), 51.6 (CH₂), 34.0 (CH₂), 32.7 (CH₂), 29.0 (CH₂), 28.3 (CH₂), 28.1 (CH₂), 28.0 (CH₂), 26.0 (CH₂), 21.5 (CH₃), 21.0 (CH₃). IR: (neat) ν = 1652 (m), 906 (s), 726 (s), 661 (m), 551 (m). HRMS (ESI) m/z : [M + H]⁺ calcd for C₂₅H₃₄⁷⁹BrN₂O₃S, 521.1474; found, 521.1475.

***N*-((2-(10-bromodecyl)-4-(*p*-tolyl)-4,5-dihydrooxazol-4-yl)methyl)-4-methylbenzenesulfonamide (4-27).**

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as colourless oil (1.331 g, 75%). ¹H NMR (CDCl₃, 400 MHz): δ 7.65 (d, 2H, J = 8.0 Hz), 7.22 (d, 2H, J = 8.0 Hz), 7.13 (d, 2H, J = 8.3 Hz), 7.08 (d, J = 8.3 Hz, 2H), 5.34 (dd, 1H, J = 9.1, 4.6 Hz), 4.73 (d, 1H, J = 8.4 Hz), 4.27 (d, 1H, J = 8.4 Hz), 3.39 (t, 2H, J = 6.9 Hz), 3.25 (dd, 1H, J = 12.7, 9.1 Hz), 3.03 (dd, 1H, J = 12.7, 4.6 Hz), 2.38 (s, 3H),

2.30 (s, 3H), 1.84 (p, 2H, $J = 6.9$ Hz), 1.66 (t, 2H, $J = 7.4$ Hz), 1.47 – 1.21 (m, 14H). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 101 MHz): δ 170.4 (C), 143.3 (C), 140.8 (C), 137.2 (C), 136.8 (C), 129.7 (CH), 129.3 (CH), 126.9 (CH), 125.3 (CH), 75.7 (CH₂), 75.2 (C), 51.5 (CH₂), 34.0 (CH₂), 32.7 (CH₂), 29.3 (CH₂), 29.3 (CH₂), 29.1 (CH₂), 29.1 (CH₂), 28.7 (CH₂), 28.1 (CH₂), 28.1 (CH₂), 26.1 (CH₂), 21.4 (CH₃), 21.0 (CH₃). HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{28}\text{H}_{40}^{79}\text{BrN}_2\text{O}_3\text{S}$, 563.1965; found, 563.1970.

1-(*p*-tolyl)-3-tosyl-10-oxa-3,12-diazabicyclo[7.2.1]dodec-9(12)-ene (**14-1**).

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as colourless oil (0.330 g, 40%). ^1H NMR (CDCl_3 , 400 MHz): δ 7.62 (d, 2H, $J = 8.3$ Hz), 7.29 – 7.22 (m, 4H), 7.18 – 7.14 (m, 2H), 5.20 (d, 1H, $J = 8.5$ Hz), 4.20 (d, 1H, $J = 8.5$ Hz), 3.81 (d, 1H, $J = 14.0$ Hz), 3.17 – 2.96 (m, 2H), 2.77 (d, 1H, $J = 13.9$ Hz), 2.57 – 2.48 (m, 1H), 2.38 (s, 3H), 2.33 (s, 3H), 2.15 (ddd, 1H, $J = 14.6$, 11.3, 3.8 Hz), 1.99 – 1.82 (m, 4H), 1.59 (ddq, 2H, $J = 10.9$, 8.0, 5.2 Hz). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 101 MHz): δ 170.1 (C), 143.4 (C), 140.9 (C), 137.1 (C), 134.6 (C), 129.7 (CH), 129.3 (CH), 127.4 (CH), 125.7 (CH), 76.8 (C), 74.5 (CH₂), 61.5 (CH₂), 49.8 (CH₂), 29.5 (CH₂), 27.2 (CH₂), 24.5 (CH₂), 23.6 (CH₂), 21.4 (CH₃), 21.0 (CH₃). IR: (neat) $\nu = 2923$ (w), 1664 (m), 1334 (m), 1159 (s), 1014 (m), 908 (m), 815 (m), 728 (s), 712 (s), 646 (m), 547 (s). HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{29}\text{N}_2\text{O}_3\text{S}$, 413.1899; found, 413.1895.

1-(*p*-tolyl)-3-tosyl-11-oxa-3,13-diazabicyclo[8.2.1]tridec-10(13)-ene (**14-2**).

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as white solid (0.614 g, 72%). ^1H NMR (CDCl_3 , 400 MHz): δ 7.65 (d, 2H, $J = 8.6$ Hz), 7.33 (d, 2H, $J = 8.2$ Hz), 7.27 (d, 1H, $J = 8.6$ Hz), 7.17 (d, 2H, $J = 8.2$ Hz), 5.52 (d, 1H, $J = 8.9$ Hz), 4.28 (d, 1H, $J = 8.9$ Hz), 3.96 (d, 1H, $J = 15.0$ Hz), 3.32 – 3.21 (m, 1H), 2.84 (d, 1H, $J = 15.0$ Hz), 2.59 (dt, 1H, $J = 13.2$, 4.1 Hz), 2.51 – 2.42 (m, 1H), 2.39 (s, 3H), 2.33 (s, 3H), 2.30 – 2.03 (m, 3H), 1.73 – 1.54 (m, 3H), 1.54 – 1.30 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 101 MHz): δ 168.7 (C), 143.5 (C), 142.9 (C), 136.9 (C), 134.7 (C), 129.6 (CH), 129.2 (CH), 127.6 (CH), 125.7 (CH), 76.5 (C), 74.9 (CH₂), 61.7 (CH₂), 52.5 (CH₂), 27.7 (CH₂), 27.3 (CH₂), 26.4 (CH₂), 22.6 (CH₂), 22.2 (CH₂), 21.4 (CH₃), 20.9 (CH₃). IR: (neat) $\nu = 2930$ (w), 1661 (m), 1335 (m), 1160 (s), 984 (m), 816 (m), 697 (m), 548 (s). HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{31}\text{N}_2\text{O}_3\text{S}$, 427.2055; found, 427.2042.

1-(4-chlorophenyl)-3-tosyl-11-oxa-3,13-diazabicyclo[8.2.1]tridec-10(13)-ene (**14-3**).

Product isolated by crystallization (DCM) as white solid (0.625 g, 70%). m.p. = 143–145 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.55 (d, 1H, $J = 8.0$ Hz), 7.27 (d, 1H, $J = 8.6$ Hz), 7.23 – 7.16 (m, 4H), 5.42 (d, 1H, $J = 9.0$ Hz), 4.13 (d, 1H, $J = 9.0$ Hz), 3.81 (d, 1H, $J = 15.0$ Hz), 3.16 (ddd, 1H, $J = 13.2$, 11.0, 3.5 Hz), 2.71 (d, 1H, $J = 15.0$ Hz), 2.46 (dt, 1H, $J = 13.2$, 4.0 Hz), 2.42 – 2.33 (m, 1H), 2.30 (s, 3H), 2.17 – 1.94 (m, 3H), 1.68 – 1.16 (m, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 101 MHz): δ 169.3 (C), 144.4 (C), 143.7 (C), 134.7 (C), 133.1 (C), 129.8 (CH), 128.7 (CH), 127.7 (CH), 127.5 (CH), 76.5 (C), 74.8 (CH₂), 61.5 (CH₂), 52.6 (CH₂), 27.8 (CH₂), 27.4 (CH₂), 26.3 (CH₂), 22.6 (CH₂), 22.2 (CH₂), 21.5 (CH₃). IR: (neat) $\nu = 2937$ (w), 1661 (m), 1332 (m), 1155 (s), 1086 (m), 999 (m), 952 (m),

816 (s), 700 (m), 648 (m), 579 (s), 563 (s), 545 (s). HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{28}\text{N}_2\text{O}_3\text{S}^{35}\text{Cl}$, 447.1509; found, 447.1508.

1-(*p*-tolyl)-3-tosyl-15-oxa-3,17-diazabicyclo[12.2.1]heptadec-14(17)-ene (**14-4**).

Product isolated via column chromatography (eluent Hexane : EtOAc = 7:3 v/v) as white solid (0.616 g, 70%). ^1H NMR (CDCl_3 , 400 MHz): δ 7.53 (d, 2H, $J = 8.3$ Hz), 7.27 (d, 2H, $J = 8.3$ Hz), 7.21 (d, 2H, $J = 8.0$ Hz), 7.12 (d, 2H, $J = 8.0$ Hz), 5.07 (d, 1H, $J = 8.8$ Hz), 4.38 (d, 1H, $J = 8.8$ Hz), 3.81 (d, 1H, $J = 14.8$ Hz), 3.13 (ddd, 1H, $J = 13.7$, 8.3, 5.3 Hz), 3.01 – 2.86 (m, 2H), 2.39 (m, 1H), 2.35 (s, 3H), 2.30 (s, 3H), 2.10 (dtt, 1H, $J = 15.9$, 7.7, 3.3 Hz), 1.83 (ddt, 2H, $J = 16.7$, 8.7, 4.4 Hz), 1.70 (ddt, 1H, $J = 10.6$, 8.7, 3.3 Hz), 1.66 – 1.45 (m, 4H), 1.20 (dtd, 2H, $J = 16.7$, 7.7, 4.4 Hz). $^{13}\text{C}\{^1\text{H}\}$ NMR (CD_3OD , 101 MHz): δ 171.4 (C), 145.2 (C), 143.3 (C), 138.3 (C), 135.2 (C), 130.8 (CH), 130.3 (CH), 128.7 (CH), 126.5 (CH), 77.7 (C), 76.9 (CH₂), 60.6 (CH₂), 51.4 (CH₂), 28.6 (CH₂), 28.3 (CH₂), 28.2 (CH₂), 25.4 (CH₂), 23.4 (CH₂), 22.4 (CH₂), 21.5 (CH₃), 21.1 (CH₃). IR: (neat) $\nu = 2931$ (w), 1662 (m), 1334 (m), 1159 (s), 1088 (m), 815 (m), 730 (s), 696 (s), 547 (s). HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{33}\text{N}_2\text{O}_3\text{S}$, 441.2212; found, 441.2208.

1-(*p*-tolyl)-3-tosyl-15-oxa-3,17-diazabicyclo[12.2.1]heptadec-14(17)-ene (**14-5**).

Product isolated via column chromatography (eluent Hexane:EtOAc = 7:3 v/v) as Pale yellow oil (0.318 g, 33%). ^1H NMR (CDCl_3 , 400 MHz): δ 7.59 (dd, $J = 8.3$, 1.4 Hz, 2H), 7.29 (d, $J = 8.3$ Hz, 2H), 7.24 (d, $J = 8.1$ Hz, 2H), 7.16 (d, $J = 8.1$ Hz, 2H), 4.99 (d, $J = 8.3$ Hz, 1H), 4.34 (d, $J = 8.3$ Hz, 1H), 3.78 (d, $J = 14.7$ Hz, 1H), 3.21 (dd, $J = 14.7$, 10.2 Hz, 1H), 3.10 (m, 2H), 2.39 (s, 3H), 2.33 (s, 3H), 1.77 – 1.63 (m, 3H), 1.43 – 1.11 (m, 15H). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 101 MHz): δ 143.4 (C), 142.3 (C), 137.1 (C), 136.1 (C), 136.0 (C), 129.7 (CH), 129.2 (CH), 127.3 (CH), 125.8 (CH), 77.0 (C), 75.4 (CH₂), 58.1 (CH₂), 51.3 (CH₂), 29.9 (CH₂), 29.7 (CH₂), 29.7 (CH₂), 29.4 (CH₂), 29.2 (CH₂), 28.7 (CH₂), 28.4 (CH₂), 27.4 (CH₂), 25.8 (CH₂), 21.5 (CH₃), 21.0 (CH₃). IR: (neat) $\nu = 2924$ (w), 1662 (w), 1334 (m), 1160 (m), 907 (s), 729 (s), 649 (m), 549 (m). HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{28}\text{H}_{39}\text{N}_2\text{O}_3\text{S}$, 483.2681; found, 483.2684.

ASSOCIATED CONTENT

Supporting information

Supporting information is available free of charge at

Supporting information contains: ^1H , ^{13}C , correlation spectroscopy (COSY) NMR spectra and Crystallographic data for compounds **4-1**, **4-9**, **4-13**, **4-20**, **4-21**, **4-23**, **5**, **7**, **9**, **14-2**, **14-3** and **14-4**..

AUTHOR INFORMATION

Corresponding Author

Prof. Ian R. Baxendale, Department of Chemistry, University of Durham, South Road, Durham, Durham, DH1 3LE, UK. <http://orcid.org/0000-0003-1297-1552>.

Authors:

Michele Ruggeri, Department of Chemistry, University of

Durham, South Road, Durham, Durham, DH1 3LE, UK.
<http://orcid.org/0000-0002-3016-1230>.

Dr Amanda W. Dombrowski, Discovery Chemistry and Technology AbbVie Inc. Waukegan Road, North Chicago, Illinois 60064. USA, <https://orcid.org/0000-0001-9596-263X>.

Dr Stevan W. Djuric, Discovery Chemistry and Technology Consulting LLC, New Bern, NC 28562.

Author Contributions

The manuscript was written through contributions of all authors. / All authors have given approval to the final version of the manuscript.

Funding Sources

We would like to thank AbbVie Inc. for funding (MR).

ACKNOWLEDGMENT

We also thank Dr Andrej Batsanov and Dr Dmitry S. Yufit of Durham University for solving the X-ray structures of compounds: **4-1**, **4-9**, **4-13**, **4-20**, **4-21**, **4-23**, **5**, **7**, **9**, **14-2**, **14-3** and **14-4**.

REFERENCES

- (1) Ruggeri, M.; Dombrowski, A. W.; Djuric, S. W.; Baxendale, I. R.; Photochemical Flow Synthesis of 3-Hydroxyazetidines. *ChemPhotoChem*, **2019**, 3(12), 1212-1218.
- (2) (a) Waschinski, C. J.; Tiller, J. C. Poly(oxazoline)s with telechelic antimicrobial Functions. *Biomacromolecules* **2005**, 6, 235-243. (b) Padmavathi V.; Mahesh K.; Subbaiah, D. R. C. V.; Deepti, D.; Reddy, G. S. Synthesis and biological activity of a new class of sulfone linked bis(heterocycles). *ARKIVOC*, **2009**, 10, 195-208. (c) Adams N.; Schubert U. S. Poly(2-oxazolines) in biological and biomedical application contexts. *Advanced Drug Delivery Reviews* **2007**, 59, 1504-1520. (d) Fik, C. P.; Krumm, C.; Muennig C.; Baur, T. I.; Salz, U.; Bock, T.; Tiller, J. C. Impact of functional satellite groups on the antimicrobial activity and hemocompatibility of telechelic poly(2-methyloxazoline). *Biomacromolecules* **2012**, 13, 165-172.
- (3) Khanum, S. A.; Khanum, N. F.; Shashikanth, M. Synthesis and anti-inflammatory activity of 2-aryloxy methyl oxazoline. *Bioorganic & Medicinal Chemistry Letters* **2008**, 18, 4597-4601.
- (4) (a) Hemin, T. R.; Pauvlik, J. M.; Schuber, E. V.; Geiszler, A. Antimalarials Synthesis and Antimalarial Activity of 1-(4-Methoxycinnamoyl)-4-(5-phenyl-4-oxo-2-oxazolin-2-yl)piperazine and Derivatives. *Journal of Medicinal Chemistry* **1975**, 18, 1216-1223. (b) Gordey, E. E.; Yadav, P. N.; Merrin, M. P.; Davies, J.; Ward, S. A.; Woodman, G. M. J.; Sadowy, A. L.; Smith, T. G.; Gossage, R. A. Synthesis and biological activities of 4-*N*-(anilinyln-[oxazolyl])-7-chloroquinolines (n = 30 or 40) against Plasmodium falciparum in vitro models. *Bioorganic & Medicinal Chemistry Letters* **2011**, 21, 4512-4515.
- (5) (a) Pirrung, M. C.; Tumey, L. N.; Raetz, C. R. H.; Jackman, J. E.; Snehaltha, K.; McClerren, A. L.; Fierke, C. A.; Gantt, S. L.; Rusche, K. M. Inhibition of the Antibacterial Target UDP-(3-O-acyl)-N-acetylglucosamine Deacetylase (LpxC): Isoxazoline Zinc Amidase Inhibitors Bearing Diverse Metal Binding Groups. *Journal of Medicinal Chemistry* **2002**, 45, 4359-4370. (b) Pirrung, M. C.; Tumey, L. N.; McClerren, A. L.; Raetz, C. R. H. High-throughput catch-and-release synthesis of oxazoline hydroxamates. Structure-activity relationships in novel inhibitors of *Escherichia coli* LpxC: in-vitro enzyme inhibition and antibacterial properties. *J. Am. Chem. Soc.* **2003**, 125, 1575-1586. (c) Waschinski, C. J.; Barnert, S.; Theobald, A.; Schubert, R.; Kleinschmidt, F.; Hoffmann, A.; Saalwachter, K.; Tiller, J. C. Insights in the Antibacterial Action

of Poly (methyloxazoline)s with a Biocidal End Group and Varying Satellite Groups. *Biomacromolecules* **2008**, 9, 1764-1771.

(6) (a) Gros, C.; Fahy, J.; Halby, L.; Dufau, I.; Erdmann, A.; Gregoire, J. M.; Ausseil, F.; Vispé, S.; Arimondo, P. B. DNA methylation inhibitors in cancer: Recent and future approaches. *Biochimie* **2012**, 94, 2280-2296. (b) Li, Q.; Woods, K. W.; Claiborne, A.; Gwaltney, S. L.; Barr, K. J.; Liu, G.; Gehrke, L.; Credo, R. B.; Hui, Y. H.; Lee, J.; Warner, R. B.; Kovar, P.; Nukkala, M. A.; Zielinski, N. A.; Tahir, S. K.; Fitzgerald, M.; Kim, K. H.; Marsh, K.; Frost, D.; Ng, S. C.; Hing, S. R.; Sham, L. Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent. *Bioorg. Med. Chem. Lett.* **2002**, 12, 465-469.

(7) (a) Coates, J.; Ingall, H.; Pearson, B.; Storer, R.; Williamson, R.; Cameron, J. Carbovir: the (-)-enantiomers is a potent and selective antiviral against human immunodeficiency virus *in-vitro*. *J. Antiviral Res.* **1991**, 15, 161-168. (b) Berranger, T.; Langlois, Y. [2+3]-Cycloadditions of enantiomerically pure oxazoline-n-oxides i: a short stereoselective synthesis of (+)-Carbovir. *Tet. Lett.* **1995**, 36, 5523-5526. (c) Diana, G. D.; Oglesby, R. C.; Akullian, V.; Carabateas, P. M.; Cutcliffe, D.; Mallamo, J. P.; Otto, M. J.; McKinlay, M. A.; Maliski, E. G.; Michalec, S. J. Structure-Activity Studies of 5-[[4-(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]-3-methylisoxazoles Inhibitors of Picornavirus Uncoating. *J. Med. Chem.* **1987**, 30, 383-388.

(8) Jiang, X.; Cao, Y.; Wang, Y.; Liu, L.; Shen, F.; Wang, R. A Unique Approach to the Concise Synthesis of Highly Optically Active Spirooxazolines and the Discovery of a More Potent Oxindole-Type Phytoalexin Analogue. *J. Am. Chem. Soc.* **2010**, 132, 15328-15333.

(9) (a) Miller, M. J.; Walz, A. J.; Zhu, H.; W. U, C.; Moraski, G.; Mollmann, U.; Tristani, E. M.; Crumbliss, A. L.; Ferdig, M. T.; Checkley, L.; Edwards, R. L.; Boshoff, H. I. Design, synthesis, and study of a mycobactin-artemisinin conjugate that has selective and potent activity against tuberculosis and malaria. *J. Am. Chem. Soc.* **2011**, 133, 2076-2079. (b) Moraski, G. C.; Markley, L. D.; Chang, M.; Cho, S.; Franzblau, S. G.; Hwang, C. H.; Boshoff, H.; Miller, M. J. Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds. *Bioorganic & Med Chem* **2012**, 20, 2214-2220.

(10) (a) Harnden, M. R.; Rasmussen, R. R. Synthesis of compounds with potential central nervous system stimulant activity. I. 2-Amino-2-oxazolin-4-one-5-spirocycloalkanes and 2-Amino-2-oxazolin-4-one-5-spiro (4'-piperidines). *J. Med. Chem.* **1969**, 12, 919-921. (b) Harnden, M. R.; Rasmussen, R. R. Synthesis of compounds with potential central nervous system stimulant activity. II. 5-Spiro-Substituted 2-Amino-2-oxazolines. *J. Med. Chem.* **1970**, 13, 305-308.

(11) (a) Padmavathi, V.; Mahesh, K.; Reddy, G. D.; Padmaja, A. Synthesis and bioassay of pyrrolyl oxazolines and thiazolines. *Euro. J. Med. Chem.* **2010**, 45, 3178-3183. (b) Padmaja, A.; Rajasekhar, C.; Muralikrishna, A.; Padmavathi, V. Synthesis and antioxidant activity of oxazolyl/ thiazolylsulfonylmethyl pyrazoles and isoxazoles. *Euro. J. Med. Chem.* **2011**, 46, 5034-5038. (c) Djuređić, E.; Vujašković, S. D.; Sakač, M.; Ajduković, J.; Gaković, A.; Kojić, V.; Bogdanović, G.; Klisurić, O.; Gašić, K. P. Synthesis and biological evaluation of some new 2-oxazoline and salicylic acid derivatives. *ARKIVOC* **2011**, (2), 83-102.

(12) (a) Adams, N.; Schubert, U. S.; "Poly(2-oxazolines) in biological and biomedical application contexts". *Advanced Drug Delivery Reviews*, **2007**, 59, 1504-1520. (b) Pfeiffer, B.; Hauenstein, K.; Merz, P.; Gertsch, J.; Altmann, K. Synthesis and SAR of C12-C13-oxazoline derivatives of epothilone A. *Bioorg. Med. Chem. Lett.* **2009**, 19, 3760-3763. (c) Umekawa, M.; Higashiyama, T.; Koga, Y.; Tanaka, T.; Noguchi, M.; Kobayashi, A.; Shoda, S.; Huang, W.; Wang, L. X.; Ashida, H.; Yamamoto, K. Efficient transfer of sialo- oligosaccharide onto proteins by combined use of a glycosynthase-like mutant of Mucor hiemalis endoglycosidase and synthetic sialo-complex-type sugar oxazoline. *Biochimica et*

Biophysica Acta **2010**, 1800, 1203-1209. (d) Pouyse, L.; Deffieux, D.; Quideau, S.; Hypervalent iodine-mediated phenol dearomatization in natural product synthesis. *Tetrahedron* **2010**, 66, 2235-2261. (e) Kurhade, S. E.; Ravula, S.; Siddaiah, V.; Bhuniya, D.; Reddy, D. S. Synthesis of novel dihydrooxazine and oxazoline based sugar hybrids from sugar azides. *Tet. Lett.* **2011**, 52, 4313-4315. (f) Kelly, A. M.; Wiesbrock, F. Strategies for the Synthesis of Poly(2-Oxazoline)-Based Hydrogels. *Macromol. Rapid Comm.*, **2012**, 33, 1632-1647. (g) Plisson, F.; Prasad, P.; Xiao, X.; Piggott, A. M.; Huang, X.; Khalil, Z.; Capon, R. J. Callyspongisines A-D: bromopyrrole alkaloids from an Australian marine sponge, *Callyspongia* sp. *Org. Biomol. Chem.* **2014**, 12, 1579-1584.

(13) Antonio, G. D.; William, B. S.; James, B. Copper complexes of oxazolines and lactone oxazolines as lubricating oil additives, ExxonMobil Research and Engineering Co., Priority to US06/529,391, November 30, 1988.

(14) Hargaden, G. C.; Guiry, P. J. Recent Applications of Oxazoline-Containing Ligands in Asymmetric Catalysis. *Chem. Rev.*, **2009**, 109, 2505-2550.

(15) Rainer, A.; Karl D.; Ruth P. S.; Arnold E. S. Tetrafluoroboric acid, an efficient catalyst in carbohydrate protection and deprotection reaction. *Carbohydrate Res.*, **1985**, 137, 282-290.

(16) Denis, C.; M. A. J. Dubois, M. A. J. Voisin-Chiret, A. S.; Bureau, R.; Choi, C.; Mousseau, J. J.; Bull, J. A. Synthesis of 3,3-Diarylazetidines by Calcium(II)-Catalyzed Friedel-Crafts Reaction of Azetidins with Unexpected Cbz Enhanced Reactivity, *Org. Lett.* **2019**, 21, 1, 300-304.

(17) (a) Hessel, V. Novel process windows – gate to maximizing process intensification via flow chemistry. *Chem. Eng. Tech.*, **2009**, 32(11), 1655-1681. (b) Baxendale, I. R. The integration of flow reactors into synthetic organic chemistry. *J. Chem. Technol. Biotechnol.* **2013**, 88, 519-552. (c) Baumann, M.; Baxendale, I. R. The synthesis of active pharmaceutical ingredients (APIs) using continuous flow chemistry. *Beilstein J. Org. Chem.* **2015**, 11, 1194-1219. (d) Plutschack, M. B.; Pieber, B.; Gilmore, K.; Seeberger, P. H. The Hitchhiker's Guide to Flow Chemistry. *Chem. Rev.* **2017**, 117(18), 11796-11893. (e) Baumann, M.; Moody, T. S.; Smyth, M.; Wharry, S. A Perspective on Continuous Flow Chemistry in the Pharmaceutical Industry. *Org. Process Res. Dev.* **2020**, DOI: 10.1021/acs.oprd.9b00524.

(18) <https://www.vapourtec.com/products/e-series-flow-chemistry-system-overview/> (assessed 16/04/2020).

(19) Smith, C. J.; Iglesias-Sigüenza, J.; Baxendale, I. R.; Ley, S. V. Batch and Flow Mode Focused Microwave Synthesis of 5-Amino-4-cyanopyrazoles and their Further Conversion to 4-amino-pyrazolopyrimidines *Org. Biomol. Chem.* **2007**, 5, 2758-2761.

(20) Smith, C. D.; Baxendale, I. R.; Lanners, S.; Hayward, J. J.; Smith S. C.; Ley, S. V. [3 + 2] Cycloaddition of Acetylenes with Azides to give 1,4-Disubstituted 1,2,3-Triazoles in a Modular Flow Reactor. *Org. Biomol. Chem.* **2007**, 5, 1559-1561.

(21) Baxendale, I. R. A Short Multistep Flow Synthesis of a Potential Spirocyclic Fragrance Component. *Chem. Eng. Technol.* **2015**, 38, 1713-1716.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60